Matrix metalloproteinase inhibitors and cancer: Trials and tribulations

Lisa Coussens, Barbara Fingleton, Lynn M. Matrisian

Research output: Contribution to journalArticle

2118 Citations (Scopus)

Abstract

For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.

Original languageEnglish (US)
Pages (from-to)2387-2392
Number of pages6
JournalScience
Volume295
Issue number5564
DOIs
StatePublished - Mar 29 2002
Externally publishedYes

Fingerprint

Matrix Metalloproteinase Inhibitors
Metalloproteases
Matrix Metalloproteinases
Neoplasms
Extracellular Matrix
Up-Regulation
Clinical Trials
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Matrix metalloproteinase inhibitors and cancer : Trials and tribulations. / Coussens, Lisa; Fingleton, Barbara; Matrisian, Lynn M.

In: Science, Vol. 295, No. 5564, 29.03.2002, p. 2387-2392.

Research output: Contribution to journalArticle

Coussens, Lisa ; Fingleton, Barbara ; Matrisian, Lynn M. / Matrix metalloproteinase inhibitors and cancer : Trials and tribulations. In: Science. 2002 ; Vol. 295, No. 5564. pp. 2387-2392.
@article{c620b26e0b5640dfac40cabd39af49cb,
title = "Matrix metalloproteinase inhibitors and cancer: Trials and tribulations",
abstract = "For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.",
author = "Lisa Coussens and Barbara Fingleton and Matrisian, {Lynn M.}",
year = "2002",
month = "3",
day = "29",
doi = "10.1126/science.1067100",
language = "English (US)",
volume = "295",
pages = "2387--2392",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5564",

}

TY - JOUR

T1 - Matrix metalloproteinase inhibitors and cancer

T2 - Trials and tribulations

AU - Coussens, Lisa

AU - Fingleton, Barbara

AU - Matrisian, Lynn M.

PY - 2002/3/29

Y1 - 2002/3/29

N2 - For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.

AB - For at least 30 years, matrix metalloproteinases (MMPs) have been heralded as promising targets for cancer therapy on the basis of their massive up-regulation in malignant tissues and their unique ability to degrade all components of the extracellular matrix. Preclinical studies testing the efficacy of MMP suppression in tumor models were so compelling that synthetic metalloproteinase inhibitors (MPIs) were rapidly developed and routed into human clinical trials. The results of these trials have been disappointing. Here we review the studies that brought MPIs into clinical testing and discuss the design and outcome of the trials in light of new information about the cellular source, substrates, and mode of action of MMPs at different stages of tumor progression. The important lessons learned from the MPI experience may be of great value for future studies of MPIs and for cancer drug development in general.

UR - http://www.scopus.com/inward/record.url?scp=0037192458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037192458&partnerID=8YFLogxK

U2 - 10.1126/science.1067100

DO - 10.1126/science.1067100

M3 - Article

C2 - 11923519

AN - SCOPUS:0037192458

VL - 295

SP - 2387

EP - 2392

JO - Science

JF - Science

SN - 0036-8075

IS - 5564

ER -